Infliximab in the treatment of refractory vasculitis secondary to heptitis C-associated mixed cryoglobulinaemia [9]

Rheumatology

Volumn 43, Issue 4, 2004, Pages 532-533

  Chandesris, M O ^a   Gayet, S ^a   Schleinitz, N ^a   Doudier, B ^a   Harlé, J Robert ^a   Kaplanski, G ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; INFLIXIMAB; INTERFERON; RIBAVIRIN; STEROID;

ADULT; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL OBSERVATION; CRYOGLOBULINEMIA; DETERIORATION; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LIVER BIOPSY; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC VASCULITIS; VIRUS PATHOGENESIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; CRYOGLOBULINEMIA; FATAL OUTCOME; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; TREATMENT FAILURE; VASCULITIS;

EID: 1842866197     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh080     Document Type: Letter

References (5)

1. Bartolucci P, Ramanoelina J, Cohen P et al. Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 2002;41:1126-32.
2. Cacoub P, Renou C, Rosenthal E et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine 2000;79:47-56.
3. Cacoub P, Costedoat-Chalumeau, Lidove O, Alric L. Cryoglobulinemia vasculitis. Curr Opin Rheumatol 2002;14:29-35.
4. Kaplanski G, Marin V, Maisonobe T et al. Increased soluble p55 and p75 tumour necrosis factor-α receptors in patients with hepatitis C-associated mixed cryoglobulinaemia. Clin Exp Immunol 2002;127:123-30.
5. Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-34.